毒蕈碱类药物为精神分裂症的治疗注入了新的活力。

IF 12.6 1区医学 Q1 ALLERGY

Allergy Pub Date : 2024-07-30 DOI:10.1038/d41573-024-00129-w

Katie Kingwell

引用次数: 0

摘要

卡鲁纳和布里斯托尔-迈尔斯-施贵宝公司的毒蕈碱激动剂KarXT有望为精神分裂症患者提供70多年来首个新的药物机制。卡鲁纳和布里斯托尔-迈尔斯-施贵宝公司的毒蕈碱激动剂 KarXT 看来将为精神分裂症患者提供 70 多年来的首个新药物机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Muscarinic drugs breathe new life into schizophrenia pipeline

查看原文本刊更多论文

Muscarinic drugs breathe new life into schizophrenia pipeline

Karuna and Bristol Myers Squibb’s muscarinic agonist KarXT looks set to offer the first new drug mechanism for patients with schizophrenia in over 70 years. Karuna and Bristol Myers Squibb’s muscarinic agonist KarXT looks set to offer the first new drug mechanism for patients with schizophrenia in over 70 years.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Allergy 医学-过敏

CiteScore

26.10

自引率

9.70%

发文量

393

审稿时长

2 months

期刊介绍： Allergy is an international and multidisciplinary journal that aims to advance, impact, and communicate all aspects of the discipline of Allergy/Immunology. It publishes original articles, reviews, position papers, guidelines, editorials, news and commentaries, letters to the editors, and correspondences. The journal accepts articles based on their scientific merit and quality. Allergy seeks to maintain contact between basic and clinical Allergy/Immunology and encourages contributions from contributors and readers from all countries. In addition to its publication, Allergy also provides abstracting and indexing information. Some of the databases that include Allergy abstracts are Abstracts on Hygiene & Communicable Disease, Academic Search Alumni Edition, AgBiotech News & Information, AGRICOLA Database, Biological Abstracts, PubMed Dietary Supplement Subset, and Global Health, among others.